vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and ThredUp Inc. (TDUP). Click either name above to swap in a different company.
ThredUp Inc. is the larger business by last-quarter revenue ($79.7M vs $57.3M, roughly 1.4× RHYTHM PHARMACEUTICALS, INC.). ThredUp Inc. runs the higher net margin — -7.0% vs -83.0%, a 76.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 18.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 11.1%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ThredUp Inc. is an American company that operates an online resale platform specializing in the sale of second-hand clothing, footwear, and accessories. Founded in 2009 and headquartered in Oakland, California, it has established itself as one of the leading resale fashion marketplaces.
RYTM vs TDUP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $79.7M |
| Net Profit | $-47.5M | $-5.6M |
| Gross Margin | 91.6% | 79.6% |
| Operating Margin | -82.2% | -8.4% |
| Net Margin | -83.0% | -7.0% |
| Revenue YoY | 36.9% | 18.5% |
| Net Profit YoY | -9.6% | 74.3% |
| EPS (diluted) | $-0.73 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $79.7M | ||
| Q3 25 | $51.3M | $82.2M | ||
| Q2 25 | $48.5M | $77.7M | ||
| Q1 25 | $32.7M | $71.3M | ||
| Q4 24 | $41.8M | $67.3M | ||
| Q3 24 | $33.3M | $61.5M | ||
| Q2 24 | $29.1M | $66.7M | ||
| Q1 24 | $26.0M | $64.5M |
| Q4 25 | $-47.5M | $-5.6M | ||
| Q3 25 | $-52.9M | $-4.2M | ||
| Q2 25 | $-46.6M | $-5.2M | ||
| Q1 25 | $-49.5M | $-5.2M | ||
| Q4 24 | $-43.3M | $-21.7M | ||
| Q3 24 | $-43.6M | $-24.8M | ||
| Q2 24 | $-32.3M | $-14.0M | ||
| Q1 24 | $-141.4M | $-16.6M |
| Q4 25 | 91.6% | 79.6% | ||
| Q3 25 | 89.3% | 79.4% | ||
| Q2 25 | 88.6% | 79.5% | ||
| Q1 25 | 88.8% | 79.1% | ||
| Q4 24 | 90.9% | 80.4% | ||
| Q3 24 | 88.5% | 79.3% | ||
| Q2 24 | 89.9% | 78.8% | ||
| Q1 24 | 89.2% | 80.1% |
| Q4 25 | -82.2% | -8.4% | ||
| Q3 25 | -102.6% | -5.3% | ||
| Q2 25 | -93.4% | -6.8% | ||
| Q1 25 | -143.7% | -7.6% | ||
| Q4 24 | -98.6% | -12.1% | ||
| Q3 24 | -132.0% | -17.0% | ||
| Q2 24 | -139.2% | -14.4% | ||
| Q1 24 | -538.7% | -19.2% |
| Q4 25 | -83.0% | -7.0% | ||
| Q3 25 | -103.1% | -5.2% | ||
| Q2 25 | -96.1% | -6.7% | ||
| Q1 25 | -151.4% | -7.3% | ||
| Q4 24 | -103.6% | -32.3% | ||
| Q3 24 | -131.2% | -40.3% | ||
| Q2 24 | -110.9% | -20.9% | ||
| Q1 24 | -544.4% | -25.7% |
| Q4 25 | $-0.73 | $-0.06 | ||
| Q3 25 | $-0.82 | $-0.03 | ||
| Q2 25 | $-0.75 | $-0.04 | ||
| Q1 25 | $-0.81 | $-0.04 | ||
| Q4 24 | $-0.71 | $-0.19 | ||
| Q3 24 | $-0.73 | $-0.22 | ||
| Q2 24 | $-0.55 | $-0.13 | ||
| Q1 24 | $-2.35 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $38.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $59.2M |
| Total Assets | $480.2M | $167.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $38.6M | ||
| Q3 25 | $416.1M | $46.2M | ||
| Q2 25 | $291.0M | $41.0M | ||
| Q1 25 | $314.5M | $41.1M | ||
| Q4 24 | $320.6M | $31.9M | ||
| Q3 24 | $298.4M | $43.7M | ||
| Q2 24 | $319.1M | $44.8M | ||
| Q1 24 | $201.2M | $50.1M |
| Q4 25 | $139.1M | $59.2M | ||
| Q3 25 | $148.8M | $59.1M | ||
| Q2 25 | $-11.9M | $60.2M | ||
| Q1 25 | $18.9M | $56.1M | ||
| Q4 24 | $21.7M | $56.3M | ||
| Q3 24 | $11.2M | $69.3M | ||
| Q2 24 | $39.3M | $86.5M | ||
| Q1 24 | $61.6M | $93.5M |
| Q4 25 | $480.2M | $167.2M | ||
| Q3 25 | $506.9M | $172.5M | ||
| Q2 25 | $372.7M | $173.6M | ||
| Q1 25 | $386.7M | $172.5M | ||
| Q4 24 | $392.3M | $171.2M | ||
| Q3 24 | $363.6M | $214.9M | ||
| Q2 24 | $381.8M | $231.2M | ||
| Q1 24 | $258.7M | $244.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-1.5M |
| Free Cash FlowOCF − Capex | — | $-3.2M |
| FCF MarginFCF / Revenue | — | -4.0% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $-1.5M | ||
| Q3 25 | $-26.6M | $6.0M | ||
| Q2 25 | $-23.3M | $344.0K | ||
| Q1 25 | $-40.4M | $5.7M | ||
| Q4 24 | $-18.8M | $663.0K | ||
| Q3 24 | $-25.2M | $3.3M | ||
| Q2 24 | $-29.1M | $-5.0M | ||
| Q1 24 | $-40.7M | $1.4M |
| Q4 25 | — | $-3.2M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $-2.9M | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | — | $-5.8M | ||
| Q1 24 | — | $267.0K |
| Q4 25 | — | -4.0% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | -3.8% | ||
| Q1 25 | — | 5.5% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | -8.7% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | — | 3.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
